Everest Medicines Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD
Key Highlights
- ➤VIS-101 first patient dosed in ASCEND Phase 2b wet AMD trial
- ➤ASCEND compares 6 mg and 9 mg VIS-101 against 2 mg aflibercept
- ➤Approximately 244 treatment-naïve wet AMD patients will participate in China
- ➤Phase 2b aims to select doses for VIS-101’s global Phase 3 program
- ➤Global Phase 3 program planned as early as 2027
Expert Statements
Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines
“Patients with wet AMD and other retinal vascular diseases have significant unmet needs, as treatment burden remains a meaningful challenge for both patients and physicians”
Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines
“Dosing the first patient in the Phase 2b ASCEND study marks an important step in the clinical development of VIS-101.”
Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines
“With encouraging efficacy, safety and durability results observed in Phase 2a, we believe VIS-101 has the potential to offer longer intervals between injections and sustained disease control.”
Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines
“ASCEND will further evaluate this potential against an established standard of care, with findings supporting future global development.”
Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines
“Our established clinical and commercial capabilities across China and other Asian markets will enable us to accelerate efforts to bring VIS-101 to patients and make this innovative therapy available to more patients.”
Everest Medicines Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD PR Newswire
SHANGHAI, Nov. 20, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced that the first patient has been treated in the ASCEND study, a randomized Phase 2b trial evaluating two doses of VIS-101 (6 mg and 9 mg) head-to-head against 2 mg aflibercept in approximately 244 treatment-naïve patients with wet age-related macular degeneration (wet AMD). The study is being conducted in China in partnership with Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. (NASDAQ: NBP).
Get started
Create a free account to read the full story.
